Report of ARBs and Increased Cancer Risk is Overstated

Study data arent sufficient for a hard-and-fast conclusion; if you are taking an ARB for hypertension, theres no cause for alarm.

Researchers who examined data from studies on angiotensin-receptor blockers (ARBs) reported that patients taking an ARB had a higher incidence of new cancer occurrence (7.2 percent) than patients who were not taking an ARB (6.0 percent). The findings, which were published in the July 2010 issue of The Lancet Oncology, got a lot of media coverage, some of which overstated the link between ARBs and cancer risk, sparking unwarranted concern by patients taking ARBs.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access